NEW YORK, Jan. 13, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
This analysis examines the historical and forecast performance for UCB in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs.
Features and benefits
* Gain insight into UCB's strategic outlook across the next 6 years* Analyze company sales forecasts by product, therapy area, lifecycle stage, geography, molecule type and source
Strategic insight into the prospects for UCB over the next six years. Picking out key strengths, weaknesses, opportunities and threats and evaluating the company's prescription pharmaceuticals outlook using a variety of cuts of the historical and forecast sales.
Your key questions answered
* Benchmark UCB's performance against key rivals in the prescription pharmaceutical sector* Examine the long-term sales potential of the monoclonal antibody Cimzia; providing a route to diversify its molecule type and therapy area offering
To order this report:
Intl: +1 805-652-2626
Copyright©2010 PR Newswire.
All rights reserved